Moonlake ImmunotherapeuticsMLTX

13F holders, Q1 2024 (March 31)
1holders
$50.23avg. 13F price*

At the end of Q1 2024, 1 institutions reported holding Moonlake Immunotherapeutics (MLTX) in their 13F filings. The largest holder was Decheng Capital LLC ($8.4M).

Company
Moonlake Immunotherapeutics
CUSIP
G4444C102
Latest filing quarter
Q3 2025

History

Number of 13F holders

01 Q1 2024: 1Q1 2024Q2 2024: 1Q2 2024Q3 2024: 1Q3 2024Q4 2024: 1Q4 2024Q1 2025: 1Q1 2025Q2 2025: 1Q2 2025Q3 2025: 1Q3 2025

Total Exit/New Position Q1 2024

InstitutionsTotal Value
New Positions1$8.4M
Exits0$0

Ownership 1 holders

Decheng Capital LLC 1.12% New 166,600 $8.4M

"% of holder's portfolio" is MLTX's weight in each manager's 13F, not the share of Moonlake Immunotherapeutics the manager owns.